BioNxt Solutions Inc. 4XT.F Stock
BioNxt Solutions Inc. Price Chart
BioNxt Solutions Inc. 4XT.F Financial and Trading Overview
| BioNxt Solutions Inc. stock price | 0.35 EUR |
| Previous Close | 0.35 EUR |
| Open | 0.36 EUR |
| Bid | 0 EUR x N/A |
| Ask | 0 EUR x N/A |
| Day's Range | 0.35 - 0.36 EUR |
| 52 Week Range | 0.27 - 1.1 EUR |
| Volume | 2.2K EUR |
| Avg. Volume | 1.92K EUR |
| Market Cap | 32.33M EUR |
| Beta (5Y Monthly) | 0.154518 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | 0 EUR |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
4XT.F Valuation Measures
| Enterprise Value | 34.27M EUR |
| Trailing P/E | N/A |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 65.35021 |
| Price/Book (mrq) | 18.421053 |
| Enterprise Value/Revenue | 69.258 |
| Enterprise Value/EBITDA | -3.352 |
Trading Information
BioNxt Solutions Inc. Stock Price History
| Beta (5Y Monthly) | 0.154518 |
| 52-Week Change | -52.12% |
| S&P500 52-Week Change | -12.62% |
| 52 Week High | 1.1 EUR |
| 52 Week Low | 0.27 EUR |
| 50-Day Moving Average | 0.34 EUR |
| 200-Day Moving Average | 0.48 EUR |
4XT.F Share Statistics
| Avg. Volume (3 month) | 1.92K EUR |
| Avg. Daily Volume (10-Days) | 100 EUR |
| Shares Outstanding | 91.21M |
| Float | 77.25M |
| Short Ratio | N/A |
| % Held by Insiders | 7.49% |
| % Held by Institutions | 0% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2021 |
| Most Recent Quarter (mrq) | June 30, 2022 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -2039.52% |
| Gross Margin | 68.16% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -77.93% |
| Return on Equity (ttm) | -546.00000000000000000000000000000000% |
Income Statement
| Revenue (ttm) | 494.77K EUR |
| Revenue Per Share (ttm) | 0.006 EUR |
| Quarterly Revenue Growth (yoy) | 1178.20% |
| Gross Profit (ttm) | 199.48K EUR |
| EBITDA | -10221384 EUR |
| Net Income Avi to Common (ttm) | -14220451 EUR |
| Diluted EPS (ttm) | -0.17 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 652.72K EUR |
| Total Cash Per Share (mrq) | 0.008 EUR |
| Total Debt (mrq) | 4.92M EUR |
| Total Debt/Equity (mrq) | 324.28 EUR |
| Current Ratio (mrq) | 0.344 |
| Book Value Per Share (mrq) | 0.019 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -7152610 EUR |
| Levered Free Cash Flow (ttm) | -2983621 EUR |
Profile of BioNxt Solutions Inc.
| Country | Germany |
| State | BC |
| City | Vancouver |
| Address | 1820 Fir Street |
| ZIP | V6J 3B1 |
| Phone | N/A |
| Website | https://xphyto.com |
| Industry | Drug Manufacturers-Specialty & Generic |
| Sector(s) | Healthcare |
| Full Time Employees | N/A |
BioNxt Solutions Inc. operates as a bioscience company in Germany, Switzerland, Austria, Israel, and Canada. It develops drug delivery methods, such as transdermal patches and oral dissolvable films designed for delivery of neurological medications; and psychedelic medicine to treat mental health-related medical conditions, including depression, anxiety, addiction, and trauma-related stress disorder. The company also develops point-of-care diagnostics comprising rapid diagnostics and biosensor screening tests for early detection and the potential for better treatment outcomes, and improved disease management; and COVID-19 PCR diagnostic kit, peri-implantitis oral biosensor, and H1N1 (swine flu) and H5N1 (avian flu) oral biosensors. In addition, it offers analytical testing and consulting services; and engages in the pathogen and oral health diagnostic and screening test, thin film drug formulation, and psychedelic pharmaceutical production and formulation businesses. The company was formerly known as XPhyto Therapeutics Corp. and changed its name to BioNxt Solutions Inc. in November 2022. BioNxt Solutions Inc. was incorporated in 2017 and is headquartered in Vancouver, Canada.
Q&A For BioNxt Solutions Inc. Stock
What is a current 4XT.F stock price?
BioNxt Solutions Inc. 4XT.F stock price today per share is 0.35 EUR.
How to purchase BioNxt Solutions Inc. stock?
You can buy 4XT.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for BioNxt Solutions Inc.?
The stock symbol or ticker of BioNxt Solutions Inc. is 4XT.F.
Which industry does the BioNxt Solutions Inc. company belong to?
The BioNxt Solutions Inc. industry is Drug Manufacturers-Specialty & Generic.
How many shares does BioNxt Solutions Inc. have in circulation?
The max supply of BioNxt Solutions Inc. shares is 92.38M.
What is BioNxt Solutions Inc. Price to Earnings Ratio (PE Ratio)?
BioNxt Solutions Inc. PE Ratio is 0.00000000 now.
What was BioNxt Solutions Inc. earnings per share over the trailing 12 months (TTM)?
BioNxt Solutions Inc. EPS is 0 EUR over the trailing 12 months.
Which sector does the BioNxt Solutions Inc. company belong to?
The BioNxt Solutions Inc. sector is Healthcare.